Trametinib Placebo

Phase 3

Trametinib Placebo is one of 17 therapeutic programs targeting Differentiated Thyroid Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Differentiated Thyroid CarcinomaActive, not recruiting

Differentiated Thyroid CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Differentiated Thyroid Carcinoma

#DrugCompanyPhaseTrials

Tafinlar

Novartis

Phase 3

1 2

Mekinist

Novartis

Phase 3

1 3

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Approved

2 4

Cabometyx

Bristol-Myers Squibb

Phase 2

1 5

Cotellic

Roche

Phase 2

1 6

Lenvima

Eisai

Phase 2

1 7

AL2846

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 9

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

1 10

Adriamycin

GGynecologic Oncology Group

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Differentiated Thyroid Carcinoma

NCT04940052

Clinical

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT04940052·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trametinib Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Trametinib Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Novartis

Trametinib Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Differentiated Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News